Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | MicrobiomeTrials← Back to trialsNCT05000294
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-12-07Est. Completion: 2026-12
Enrollment target: 29 participants Locations- University of Florida, Gainesville, Florida, United States
Other microbiome trials you might be interested in
Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
This is a multicenter, open-label, single-arm, prospective Phase II clinical trial. The study enrolls patients with extr…
Multiple LocationsEst. completion Feb 28, 2029
Hepatocellular Carcinoma (HCC)
The combination of HAIC with systemic therapy can provide superior efficacy compared to systemic therapy alone or local …
Beijing, ChinaEst. completion Dec 30, 2026
Phase 2
Recruiting
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic NeoplasmsSquamous Cell Carcinoma of Head and NeckEsophageal Squamous Cell CarcinomaCholangiocarcinomaGallbladder NeoplasmsColorectal NeoplasmsPancreatic Ductal AdenocarcinomaCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and tor…
Beijing, ChinaEst. completion Jun 15, 2028